$1.93
0.084.62%
At close: -
$1.92
-0.0050-0.26%
After Hours: Nov 22, 7:02 PM EDT
Comments
Loading...
Latest news for Immutep (NASDAQ:IMMP) Stock
Immutep Stock (NASDAQ: IMMP)
Categories: All
Friday, November 15, 2024
Thursday, November 14, 2024
Monday, October 28, 2024
Thursday, October 17, 2024
Thursday, October 03, 2024
Tuesday, September 24, 2024
Wednesday, September 18, 2024
Monday, September 16, 2024
Tuesday, August 20, 2024
Wednesday, August 14, 2024
Monday, July 29, 2024
Monday, July 22, 2024
Wednesday, July 17, 2024
Monday, July 15, 2024
Friday, July 12, 2024
- Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Market-Moving News for July 12th
- Immutep shares are trading higher after the c...
- Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
- Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- Reported Earlier, Immutep Announces Results F...
Thursday, June 27, 2024
Tuesday, June 25, 2024
Wednesday, June 05, 2024
Monday, June 03, 2024
Friday, May 17, 2024
Thursday, May 02, 2024
Monday, April 29, 2024
Wednesday, April 24, 2024
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Immutep shares are trading higher after the c...
- Immutep Announced Tuesday, Data From Efti In Combination With Keytruda In First Line Head And Neck Squamous Cell Carcinoma Patients Who Do Not Express PD-L1 Shows A Preliminary 26.9% Response Rate, The Primary Endpoint Of The Study